Ken Griffin Syndax Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 38,000 shares of SNDX stock, worth $497,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,000

Previous 25,000 52.0%

Holding current value

$497,040

Previous $513,000 42.5%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.93 - $24.81 $2.8 Million - $3.87 Million	-155,961 Reduced 82.09%	34,020 $654,000
Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $2.94 Million - $3.72 Million	156,172 Added 461.92%	189,981 $3.9 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $4.12 Million - $5.14 Million	-209,176 Reduced 86.09%	33,809 $804,000
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $2.19 Million - $4.17 Million	-192,508 Reduced 44.2%	242,985 $5.25 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $2.88 Million - $4.32 Million	198,543 Added 83.79%	435,493 $6.32 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $26 Million - $30 Million	-1,342,719 Reduced 85.0%	236,950 $4.96 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $995,481 - $1.4 Million	-48,184 Reduced 2.96%	1,579,669 $33.4 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $5.39 Million - $6.85 Million	261,082 Added 19.1%	1,627,853 $41.4 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $6.71 Million - $8.98 Million	-362,281 Reduced 20.95%	1,366,771 $32.8 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $1.31 Million - $1.88 Million	-96,388 Reduced 5.28%	1,729,052 $33.3 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $2.87 Million - $4.28 Million	-193,387 Reduced 9.58%	1,825,440 $31.7 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $2.67 Million - $3.94 Million	175,470 Added 9.52%	2,018,827 $44.2 Million
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $1.6 Million - $2.28 Million	-115,274 Reduced 5.89%	1,843,357 $35.2 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $3.64 Million - $6.84 Million	-271,492 Reduced 12.17%	1,958,631 $33.6 Million
Q1 2021 May 17, 2021	BUY	$19.28 - $24.59 $2.29 Million - $2.92 Million	118,605 Added 5.62%	2,230,123 $49.9 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $23.4 Million - $41 Million	1,549,104 Added 275.44%	2,111,518 $47 Million
Q3 2020 Nov 16, 2020	SELL	$13.39 - $17.48 $6.42 Million - $8.38 Million	-479,166 Reduced 46.0%	562,414 $8.3 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $9.19 Million - $21.6 Million	1,028,435 Added 7823.77%	1,041,580 $15.4 Million
Q1 2020 May 15, 2020	SELL	$6.65 - $12.03 $60,202 - $108,907	-9,053 Reduced 40.78%	13,145 $144,000
Q4 2019 Feb 14, 2020	SELL	$5.43 - $9.22 $69,552 - $118,098	-12,809 Reduced 36.59%	22,198 $195,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $82,972 - $194,064	-23,048 Reduced 39.7%	35,007 $155,000
Q3 2018 Nov 13, 2018	BUY	$6.33 - $8.08 $225,075 - $287,300	35,557 Added 158.05%	58,055 $0
Q2 2018 Aug 10, 2018	BUY	$6.93 - $14.63 $155,911 - $329,145	22,498 New	22,498 $0

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account